Another week, another new deal for Palantir Technologies (NASDAQ: PLTR). This time, the AI powerhouse is partnering with OneMedNet (NASDAQ: ONMD) to bring its Artificial Intelligence Platform (AIP) into healthcare — fueling growth in real-world imaging data, oncology, and clinical research.
2 extracted signals · 2 resolved · 0 still active
MarketBeat18 Oct 2025, 01:00 UTC
AI-generated source summary
Palantir is analyzed with a focus on its healthcare deals, including a partnership with OneMedNet, the video discusses its healthcare aspect, noting Palantir's presence in healthcare with contracts with pharmaceutical companies. The video looks ahead to earnings report with mention to pattern of the stock chopping around in a range leading into the earning and the possibility for uptrend price. Piper Sandler came in Tuesday and raise their price target from 182 to 201. Analysts consensus price target for MarketBeat has already gone up to 141.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from MarketBeat
This Is Why Meta Stock is Dumping
5 Hot Stocks to Buy Now: August's Top Tech Picks With Upside Ahead
He Told You to Buy the Dip. Now It's Up 20%.
If I Started Investing in 2026, This is What I Would Do
This January Deadline Will Send Demand Soaring in This Sector.
3 ENERGY Stocks With Big Potential Catalysts
MarketBeat
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.